Biomea Fusion, Inc. · NASDAQ:BMEA
Biomea Fusion — EASD Annual Meeting 2022
10 slides from Biomea Fusion's conference presentation, Sep 22, 2022
Slide 1: Oral Menin Inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a Type 2 Diabetes Rat Model
Exhibit 99.2 Presentation #590 Oral Menin Inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a Type 2 Diabetes Rat Model Priyanka Somanath, Sanchita Mourya, Weiqun Li, Tenley Archer, Brian Law, Daniel Lu, Tripta Rughwani, Lekha Kumar, Taisei Kinoshita, Mini Balakrishnan, Th
Slide 2: Menin: A novel target for beta-cell homeostasis
Menin: A novel target for beta-cell homeostasis Potential Mechanism of Menin in Diabetes BMF-219: A selective covalent menin inhibitor ▪ Menin is an epigenetic protein that plays a key role in regulating NPM1 beta-cell proliferation and function. BMF-219 covalent binding to menin disrupts menin MYC
Slide 3: Study Design: Zucker Diabetic Fatty (ZDF) rat model of T2DM
Study Design: Zucker Diabetic Fatty (ZDF) rat model of T2DM Treatment Scheme of ZDF Rat Model THE ZDF RAT Day: 0 8 15 21 28 43 56 Daily oral dosing (QD) Drug wash out Group 1 dose study last dose increased from 40 to termination 200 mg/day Treatment groups (n=10/group): 1. Vehicle Rats monitored thr
Slide 4: BMF-219 substantially controls blood glucose levels in a 4-week dosing study in ZDF rats
BMF-219 substantially controls blood glucose levels in a 4-week dosing study in ZDF rats * p<0.05 ** p<0.001 4hr Fasting Blood Glucose **** p<0.0001 4 hr Fasting Blood Glucose Vehicle 800 600 ✱ BMF-219 40 mg/kg (Day 1-16), ✱✱ ✱✱✱ ✱✱✱✱ 200mg/kg (Day 17-28) PO ✱✱ ✱ 600 500 Liraglutide 0.2 mg/kg BID 40
Slide 5: BMF-219 substantially controls blood glucose levels in a 4-week dosing study in ZDF rats
BMF-219 substantially controls blood glucose levels in a 4-week dosing study in ZDF rats * p<0.05 ** p<0.001 4hr Fasting Blood Glucose **** p<0.0001 4 hr Fasting Blood Glucose Vehicle 800 600 ✱ BMF-219 40 mg/kg (Day 1-16), ✱✱ ✱✱✱ ✱✱✱✱ 200mg/kg (Day 17-28) PO ✱✱ ✱ 600 500 Liraglutide 0.2 mg/kg BID 40
Slide 6: BMF-219 restores beta-cell function over weeks of treatment
BMF-219 restores beta-cell function over 4 weeks of treatment 4 hr Fasting HOMA-B (Day 21) 4 hr Fasting HOMA-B (Day 29) BMF-219 restores and maintains HOMA-B index to Last day of treatment normal state (>201) over 4 weeks of treatment 400 400 HOMA-B (4 hr Fasting) 300 300 250 200 200 200 BMF-219 (17
Slide 7: BMF-219 significantly reduces HbA1c (-3.5%) during treatment and maintains lowering effect during washout
BMF-219 significantly reduces HbA1c (-3.5%) during treatment and maintains lowering effect during 2 weeks of drug washout Hemoglobin A1c (%) * p<0.05 ** p<0.01 ****p<0.0001 * BMF-219 Day 29: ✱✱✱✱ ✱✱✱✱ 15 3.5% HbA1c reduction ✱✱✱✱ ✱✱✱✱ Vehicle 0mg/kg * 10 BMF-219 40mg/kg (days 1-16), 200mg/kg (days 1
Slide 8: BMF-219 treated groups display body weight and cholesterol reduction
BMF-219 treated groups display body weight and cholesterol reduction BMF-219 200 mg/kg group reduces body weight during BMF-219 reduces blood lipemic levels measured treatment in ZDF rats on Day 29 Total Cholesterol Triglycerides Body weight 425 *** p<0.0005 ✱✱✱✱ ****p<0.0001 400 ✱✱✱ 250 1000 375 20
Slide 9: Summary and Conclusions
Summary and Conclusions ➢ BMF-219 displays significant glycemic control in ZDF rats, outperforming liraglutide in reduction of fasting blood glucose by Day 29 and by OGTT on day 25. ➢ BMF-219 significantly reduces HbA1c levels (-3.5%) during treatment and drug washout. ➢ BMF-219 treatment restores H
Slide 10: Biomea Fusion
() biomea FUSION”